MentalHealthDaily

Effects of Pramipexole on Reward Learning: Possible Depression Treatment? (2023 Study)

In a significant stride toward understanding and treating depression, a 2023 study meticulously investigates the effects of pramipexole, a dopamine D2-like agonist, on reward learning. By exploring its impact on healthy volunteers through rigorous behavioral and neural assessments, the research offers groundbreaking insights into how this drug (occasionally used in depression) could revolutionize therapeutic strategies …

Mirapex (Pramipexole) For Depression: An Effective Antidepressant?

by GLOOM

Mirapex (Pramipexole) is a drug that is approved by the FDA for the treatment of Parkinson’s disease and RLS (restless leg syndrome). Classified as a dopamine receptor agonist, pramipexole elicits partial or full agonism upon D3 receptors, D2 receptors (2L/2S), and D4 receptors. Interestingly, pramipexole also appears to modify mitochondrial function, and to a negligible …

Mirapex (Pramipexole) Side Effects & Adverse Reactions (List)

by GLOOM

Mirapex (Pramipexole) is a medication that was approved by the FDA in 1997 for the treatment of idiopathic (early-stage and advanced) Parkinson’s disease. Analysis of the drug’s pharmacodynamics reveals its function as a mixed partial/full dopamine agonist, with highest affinity for: D3 receptors, D2 receptors (D2S and D2L), and D4 receptors (in that order). To …